Skip to main content
. 2017 Dec 22;7(12):e016368. doi: 10.1136/bmjopen-2017-016368

Table 2.

Association between paternal SSRI use before conception and ASD in offspring

Paternal SSRI use before conception Offspring with ASD, n Follow-up number of person-years HR (95% CI)
Crude Model 1* Model 2†
No use during the last 3 months prior to conception 7473 6 765 205 Ref Ref Ref
Use during the last 3 months prior to conception 104 61 555 1.62 (1.33 to 1.96) 1.54 (1.27 to 1.88) 1.43 (1.18 to 1.74)
Subanalysis: paternal SSRI use during the last 1  year before conception
No use during the last 1 year prior to conception 7429 6 736 654 Ref Ref Ref
Use only from the last 1 year to the last 3 months prior to conception 71 39 422 1.71 (1.35 to 2.16) 1.66 (1.31 to 2.09) 1.54 (1.21 to 1.94)
Use only during the last 3 months prior to conception 20 14 738 1.29 (0.83 to 2.00) 1.24 (0.80 to 1.93) 1.17 (0.75 to 1.82)
Use both before and during the last 3 months prior to conception 57 35 946 1.52 (1.17 to 1.97) 1.43 (1.10 to 1.86) 1.32 (1.02 to 1.72)

*Adjusted for calendar year of birth, sex, parity, mother age, father age, maternal smoking, mother psychiatric history, maternal AD use during pregnancy.

†Model 1 further adjusted for father psychiatric history.

AD, antidepressant drug; ASD, autism spectrum disorder; n, number; SSRI, selective serotonin reuptake inhibitor.